COUNTRY:  EASTERN AFRICA.

Countries in the Intergovernmental Authority on Development (IGAD) are working towards a common framework for regulating locally manufactured medicines. The initiative was discussed at a regional workshop that opened in Addis Ababa, Ethiopia, on October 19, 2026. According to APA News, the proposed framework aims to improve pharmaceutical standards, strengthen local manufacturing and expand access to quality-assured medicines. The effort also addresses a major challenge facing manufacturers: the high cost of conducting medicine tests outside the region. By improving local testing capacity and aligning national requirements, IGAD states hope to make medicine development and approval more efficient. The initiative builds on IGAD’s existing Medicines Regulation Harmonization Programme, which supports cooperation between national regulators and the development of local pharmaceutical production.

The workshop focused on bioavailability and bioequivalence testing, which helps determine whether a generic medicine performs comparably to an established reference medicine. These tests provide important evidence for regulators assessing medicines before approval. However, IGAD’s 2024 study found that regional testing capacity and specialist expertise remain limited. As a result, manufacturers often send studies abroad, increasing costs and extending approval timelines. A World Health Organization report on IGAD regulatory training also highlights efforts to improve how regional experts assess bioequivalence studies. Stronger local capacity could help manufacturers meet regulatory requirements while supporting patient safety. It could also encourage universities, research institutions and pharmaceutical companies to invest in specialised facilities and expertise within the region.

IGAD brings together Djibouti, Ethiopia, Kenya, Somalia, South Sudan, Sudan and Uganda. A shared approach could help manufacturers navigate different national rules and reach more markets across the region. It could also create stronger conditions for investment in testing centres, research and medicine production. However, the proposed framework is still under development, and its success will depend on funding, skilled personnel, accredited facilities and effective regulatory oversight. Harmonising requirements alone will not guarantee affordable medicines or end dependence on imported pharmaceutical products. Governments must also support local manufacturers and ensure that medicines meet rigorous quality standards. If implemented effectively, the initiative could strengthen regional pharmaceutical capacity and give East African countries greater control over an essential part of their healthcare systems.

PHOTO SOURCE: ACCORD
Author: Randy Lawson.